NFG
ACAD icon

Next Financial Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Next Financial Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$0 Hold
8
– – ﹤0.01% 2846
2021
Q3 		$0 Sell
8
-19
-70% -$366 ﹤0.01% 2731
2021
Q2 		$0 Sell
27
-935
-97% -$21.1K ﹤0.01% 2611
2021
Q1 		$25K Buy
962
+443
+85% +$19.5K ﹤0.01% 1554
2020
Q4 		$28K Buy
519
+19
+4% +$943 ﹤0.01% 1405
2020
Q3 		$21K Buy
+500
New +$21.6K ﹤0.01% 1383
2020
Q1 		– Sell
-400
Closed -$17K – 2094
2019
Q4 		$17K Buy
+400
New +$17.4K ﹤0.01% 1573
2019
Q3 		– Sell
-100
Closed -$3K – 2290
2019
Q2 		$3K Sell
100
-7,900
-99% -$202K ﹤0.01% 1984
2019
Q1 		$215K Sell
8,000
-1,637
-17% -$38.2K 0.05% 342
2018
Q4 		$156K Buy
9,637
+1,137
+13% +$22.1K 0.03% 455
2018
Q3 		$176K Buy
+8,500
New +$134K 0.08% 225
2017
Q4 		– Sell
-200
Closed -$7K – 284
2017
Q3 		$7K Hold
200
– – ﹤0.01% 1318
2017
Q2 		$6K Hold
200
– – ﹤0.01% 1475
2017
Q1 		$7K Hold
200
– – ﹤0.01% 1386
2016
Q4 		$6K Hold
200
– – ﹤0.01% 1837
2016
Q3 		$6K Hold
200
– – ﹤0.01% 1843
2016
Q2 		$6K Sell
200
-300
-60% -$10K ﹤0.01% 1348
2016
Q1 		$13K Sell
500
-1,000
-67% -$21.8K ﹤0.01% 1070
2015
Q4 		$53K Buy
1,500
+100
+7% +$3.52K 0.02% 601
2015
Q3 		$46K Sell
1,400
-1,000
-42% -$41.6K 0.02% 652
2015
Q2 		$100K Sell
2,400
-100
-4% -$3.87K 0.03% 466
2015
Q1 		$81K Hold
2,500
– – 0.03% 520
2014
Q4 		$79K Hold
2,500
– – 0.03% 528
2014
Q3 		$62K Hold
2,500
– – 0.01% 842
2014
Q2 		$53K Buy
+2,500
New +$52.2K 0.03% 334

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Next Financial Group's ACAD Position: Q4 2021 in Review

Next Financial Group held its Acadia Pharmaceuticals (ACAD) position steady in Q4 2021 at 8 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2846.

Next Financial Group first reported a position in ACAD in Q2 2014 and has held it in 25 quarters since. The position peaked at $215K in Q1 2019. 246 funds tracked by Wall St. Rank hold ACAD as of Q4 2021.

  • Next Financial Group held 8 shares of Acadia Pharmaceuticals worth $0 as of Q4 2021.
  • Next Financial Group left its Acadia Pharmaceuticals share count unchanged in Q4 2021.
  • Acadia Pharmaceuticals made up ﹤0.01% of Next Financial Group's portfolio in Q4 2021, its #2846 holding.
  • Next Financial Group first reported a position in Acadia Pharmaceuticals in Q2 2014 and has held it in 25 quarters since.
  • Next Financial Group's Acadia Pharmaceuticals position peaked at $215K in Q1 2019.
  • 246 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2021.

Based on Next Financial Group's 13F filing for Q4 2021, filed 15 Feb 2022.